Alumis Inc. ALMS
6.27 USD -0.35 (-5.29%)
Nov 12, 2026, 3:46 PM EST
6.23 Day range 6.61
4.60 52-week range 31.35
- YTD
- -35.76%
- 1 year
- +19.66%
News
defenseworld.net Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27 According to Brokerages Shares of Alumis Inc. (NASDAQ: ALMS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen research firms that are covering the stock, Marketbeat.com reports.…
benzinga.com Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026 – Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis–…
benzinga.com Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37 Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $55 to $37.
benzinga.com Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25 Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $51 to $25.
benzinga.com Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
benzinga.com This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Analysts upgraded Alumis, Sirius XM, OGE Energy, revising their price targets and outlooks.- benzinga.com Morgan Stanley Maintains Overweight on Alumis, Lowers Price Target to $29 Morgan Stanley analyst Terence Flynn maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $39 to $29.
benzinga.com HC Wainwright & Co. Upgrades Alumis to Buy, Lowers Price Target to $15 HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Alumis (NASDAQ:ALMS) from Neutral to Buy and lowers the price target from $25 to $15.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regular session. The company's market cap stands at $2.7 million. USBC (AMEX:USBC) stock moved upwards by…
benzinga.com Crude Oil Surges 3%; ISM Manufacturing PMI Falls In August U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday.The Dow traded down 0.40% to 52,971.81 while the NASDAQ dipped 0.52% to 26,232.46.…
benzinga.com Why Is Alumis Stock Falling Tuesday? Alumis (ALMS) stock drops over 50% after Phase 2b lupus trial misses overall endpoints, but sub-group data shows promise.
benzinga.com Dow Dips Over 300 Points; Medtronic Shares Gain After Upbeat Q1 Earnings U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.58% to 52,876.43 while the NASDAQ…
benzinga.com Alumis Announces Its Phase 2b LUMUS Study Of Envudeucitinib To Treat Lupus Erythematosus Failed To Meet Primary, Secondary Endpoints Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that its Phase 2b LUMUS…- benzinga.com HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral and maintains $25 price target.
- benzinga.com Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per…
benzinga.com Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.
benzinga.com Alumis Reports Topline Results From Ongoing ONWARD3 Long-Term Extension Study Showing 54% Of Patients Reached Complete Skin Clearance After 48 Weeks Of Continuous Envudeucitinib Treatment – Favorable long-term safety and tolerability profile remained consistent with previously reported data –– On track to submit a New Drug Application to FDA in 4Q 2026 –SOUTH SAN FRANCISCO, Calif.,…- benzinga.com HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral and maintains $25 price target.
- benzinga.com Chardan Capital Maintains Buy on Alumis, Raises Price Target to $40 Chardan Capital analyst Janani Sundararajan maintains Alumis (NASDAQ:ALMS) with a Buy and raises the price target from $38 to $40.
benzinga.com This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & UNTY with Buy ratings. See other analyst views.
benzinga.com Wells Fargo Maintains Overweight on Alumis, Raises Price Target to $51 Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and raises the price target from $49 to $51.
benzinga.com Guggenheim Maintains Buy on Alumis, Raises Price Target to $34 Guggenheim analyst Yatin Suneja maintains Alumis (NASDAQ:ALMS) with a Buy and raises the price target from $32 to $34.
benzinga.com This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.
benzinga.com Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at benzinga.com/analyst-stock-ratings
benzinga.com This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst ratings page. Analysts' thoughts on LGND stock.
benzinga.com This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday 
benzinga.com This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday 
benzinga.com This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday 
benzinga.com Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday 
benzinga.com This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday 
benzinga.com David Vs. Goliath: Why Small Cap Stocks Are Crushing The Magnificent 7 The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small-cap earnings expectations rise.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com What's Going On With Alumis Stock Thursday? Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune disease pipeline.
benzinga.com Dow Jumps Over 400 Points; US Services Activity Falls In December 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday 
benzinga.com US Stocks Mixed; Nasdaq Gains Over 50 Points - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket - benzinga.com Alumis And Acelyrin Issue Breach Notice To Climb Bio Over Unpaid $3M Milestone Due January 1, 2026 On January 2, 2026, Alumis Inc. (the "Company") and its wholly-owned subsidiary Acelyrin, Inc. ("Acelyrin") issued a Notice of Material Breach and Notification of Claim for Indemnification to Climb…
benzinga.com Honeywell, Intuitive Machines And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com ServiceTitan Posts Upbeat Q3 Results, Joins DigitalBridge, Rubrik, Victoria's Secret And Other Big Stocks Moving Higher On Friday 
benzinga.com Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday 
benzinga.com Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session